Need for Panretinal Photocoagulation Reduced After Anti-VEGF
The intravitreal injections may reduce the activity of proliferative diabetic retinopathy, according to a report.
The intravitreal injections may reduce the activity of proliferative diabetic retinopathy, according to a report.
The OCT finding correlates with reduced visual acuity, according to a study.
The intravitreal injection improves acuity and reduces retinal fluid in a 12-week therapy regimen for patients with diabetic macular edema, researchers report.
The drug-delivery device maintained efficacy after 3 years, researchers say.
Vabysmo is a humanized bispecific antibody that works by inhibiting the angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) pathways.
Patients who receive more frequent anti-VEGF injections for diabetic macular edema have a marginally higher death risk, research shows.
Researchers found that, following anti-VEGF therapy, patients with DME mainted retinal thickness, but lost letters of visual acuity at 2 and 5 year follow-up appointments.
Patients with diabetic macular edema experienced lower total retinal blood flow than patients without.
The drug mproves visual and anatomic outcomes among eyes experiencing visual loss after laser diabetic macular edema treatment.
An algorithm based on deep machine learning may help identify diabetic retinopathy and diabetic macular edema with high specificity and sensitivity.